Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 7, 2007, Pages 657-660

  Ågren, Anna ^a   Wiman, Björn ^a   Schulman, Sam ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Bleeding; Fibrinolysis; Plasminogen activator inhibitor

Indexed keywords

ANTIPLASMIN; D DIMER; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; FEMALE; HUMAN; HYPERFIBRINOLYSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPLASMIN; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HEMORRHAGIC DISORDERS; HUMANS; MALE; MIDDLE AGED; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; RETROSPECTIVE STUDIES; SWEDEN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34748851893     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282dded21     Document Type: Article

References (26)

1. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83:1747-1752.
2. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EK. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77:528-532.
3. Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81:2357-2362.
4. Tanimura LK, Weddell JA, McKown CG, Shapiro AD, Mulherin J. Oral management of a patient with a plasminogen activator inhibitor (PAI-1) deficiency: case report. Pediatr Dent 1994; 16:133-135.
5. Takahashi Y, Tanaka T, Minowa H, Ookubo Y, Sugimoto M, Nakajima M, et al. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency. Int J Hematol 1996;64:61-68.
6. Minowa H, Takahashi Y, Tanaka T, Naganuma K, Ida S, Maki I, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis 1999; 29:286-291.
7. Morimoto Y, Yoshioka A, Imai Y, Takahashi Y, Minowa H, Kirita T. Haemostatic management of intraoral bleeding in patients with congenital deficiency of alpha2-plasmin inhibitor or plasminogen activator inhibitor-1. Haemophilia 2004; 10:669-674.
8. Repine T, Osswald M. Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review. Clin Appl Thromb Hemost 2004; 10:293-296.
9. Favier R, Aoki N, de Moerloose P. Congenital alpha(2)-plasmin inhibitor deficiencies: a review. Br J Haematol 2001; 114:4-10.
10. Leander K, Wiman B, Hallqvist J, Sten-Linder M, de Faire U. PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of nonfatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP). Thromb Haemost 2003; 89:1064-1071.
11. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557-1563.
12. Segui R, Estelles A, Mira Y, Espana F, Villa P, Falco C, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 2000; 111:122-128.
13. Schulman S, Lindmarker P, Holmstrom M, Lärfars G, Carlsson A, Nicol P, et al. Postthrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4:734-742.
14. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75:902-907.
15. Kornelisse RF, Hazelzet JA, Savelkoul HF, Hop WC, Suur MH, Borsboom AN, et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996; 173:1148-1156.
16. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002; 87:1419-1422.
17. Vague P, Raccah D, Scelles V. Hypofibrinolysis and the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995; 19 (Suppl 1):S11-S15.
18. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemost 1989; 61:370-373.
19. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24:195-208.
20. Ågren A, Wiman B, Stiller V, Lindmarker P, Sten-Linder M, Carlsson A, et al. Evaluation of low PAI-I activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006; 4:201-208.
21. Ågren A, Kolmert T, Wiman B, Schulman S. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thromb Res 2007; 119:715-721.
22. Holvoet P, de Boer A, Verstreken M, Collen D. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma - application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost 1986; 56:124-127.
23. Wiman B, Jacobsson L, Andersson M, Mellbring G. Determination plasmin-a2-antiplasmin complex in plasma by means of a radioimmunoassay. Scand J Clin Lab Invest 1983; 43:27-33.
24. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327:1729-1733.
25. Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care 2003; 31:529-537.
26. Sylvan A, Rutegard JN, Janunger KG, Sjolund B, Nilsson TK. Normal plasminogen activator inhibitor levels at long-term follow-up after jejunoileal bypass surgery in morbidly obese individuals. Metabolism 1992; 41:1370-1372.